Chicken subunit bivalent vaccine, as well as preparation and application thereof

A dual vaccine and vaccine adjuvant technology, applied in the direction of antiviral agents, virus antigen components, etc., can solve problems such as interference with laboratory diagnosis of virus isolation, easy to cause respiratory side effects, and immune susceptibility to maternal antibody interference.

Active Publication Date: 2013-03-20
QINGDAO VLAND BIOTECH INC +1
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the Newcastle disease live vaccine is effective, cheap and easy to use, it has a short immunization period and is easily interfered by maternal antibodies, and it is easy to cause respiratory side effects and interfere with laboratory diagnosis of virus isolation. Therefore, since 1980, Newcastle disease inactivated vaccines have been used Vaccine has gradually become one of the routine methods for preventing and controlling Newcastle disease in chicken farms in my country

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chicken subunit bivalent vaccine, as well as preparation and application thereof
  • Chicken subunit bivalent vaccine, as well as preparation and application thereof
  • Chicken subunit bivalent vaccine, as well as preparation and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0010] The main structural protein VP2 protein of IBDV is the most important host protective antigen. The present invention amplifies the super-virulent VP2 gene of IBD by PCR method, clones it on the pET-28a vector, transforms BL21(DE3), and induces it with IPTG After the VP2 protein is expressed, the expressing cells are homogenized under high pressure and then centrifuged to obtain the supernatant, which is the VP2 protein solution.

[0011] Newcastle disease virus Clone30 strain was inoculated into 10-day-old SPF embryos, and the embryos cultured for 72-120 hours after inoculation were selected to harvest the embryo fluid. The virus fluid was concentrated by ultrafiltration and concentration, and 0.1% formaldehyde was added to the final concentration.

[0012] Mix the VP2 protein solution with the Newcastle disease virus solution and then emulsify the vaccine.

[0013] The chicken Newcastle disease-infectious bursal virus VP2 subunit dual vaccine of the present invention w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to preparation and application of a newcastle disease-infectious bursal disease VP2 subunit bivalent vaccine. The preparation comprises the following steps of performing egg inoculation on a newcastle disease Clone30 strain to obtain blastochyle, and inactivating; mixing with chicken infectious bursal disease VP2 protein liquid of bacillus coli in a certain proportion; adding mineral oil adjuvant, and emulsifying to obtain bivalent vaccine; immunizing a 21-day SPF (specific pathogen free)chick with the bivalent vaccine; performing toxicity attack on newcastle disease virulent strain isolated in Beijing and infectious bursal disease virulent BC6-85 respectively after 21 days of immunization, results indicate that light bursa fabricius symptom appears on a chick in 20 chicken in the immunized group, and the rest chicken does not have abnormality; and 10/10 chicken are attacked and dead in the newcastle disease control group, and 8/10 chicken in the infectious bursal disease virus attack control group are attacked.

Description

technical field [0001] The invention belongs to the field of poultry vaccine production, and in particular relates to a chicken subunit dual vaccine and its preparation and application, that is, a chicken Newcastle disease-infectious bursal disease dual vaccine. Background technique [0002] Newcastle disease (ND) is an acute infectious disease of poultry caused by Newcastle disease virus (NDV). Although the Newcastle disease live vaccine is effective, cheap and easy to use, it has a short immunization period and is easily interfered by maternal antibodies, and it is easy to cause respiratory side effects and interfere with laboratory diagnosis of virus isolation. Therefore, since 1980, Newcastle disease inactivated vaccines have been used Vaccines have gradually become one of the conventional methods for preventing and controlling Newcastle disease in chicken farms in my country. [0003] Chicken infectious bursal disease (Infectious Bursal Disease, IBD), also known as chic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/17A61K39/12A61P31/14
Inventor 王雷凌红丽蒋贻海
Owner QINGDAO VLAND BIOTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap